Bonjour / Se connecter
Listings
Accès
Agenda
Actualités
Médecins généralistes

Spécialisations

  • Médecine interne (Université de Liège, 1976)
  • Cinétique des populations cellulaires (Attestation d'études approfondies AEA, Paris, 1975)
  • Sciences biomédicales (Université de Liège, 1985)
  • European Society of Medical Oncology examination (Florence, 1991)
  • Molecular Genetics in solid tumors for clinical oncologists (Ascona, CH, 1997)
  • Reconnu Medecin spécialiste en Oncologie Médicale (2008)

Centres d'intérêt

  • Oncologie médicale

  • Hématologie

  • Chronobiologie et chronothérapie

  • Pharmaco-cinétique

  • Recherches cliniques de phase I, II et III

Mandats

  • Maître de stage (Université de Liège)

  • Membre de la Belgian Society for Medical Oncology (BSMO)

  • Membre de  l'European Society for Medical Oncology (ESMO)

  • Membre de l'American Society of Clinical Oncology (ASCO)

  • Membre de l'American Association for Cancer Research (AACR)

  • Membre de la New-York Academy of Sciences

  • Coordinateur du Groupe régional d'Etudes du Cancer Colo-Rectal (GRECCR, 1990)

  • Président de l'Association française de chronobiologie médicale (AFCM, 1998)

  • Président de l'European Organisation for Research and Treatment of Cancer (EORTC – Chronotherapy Group, 2002)

  • Trésorier de l'Association pour la Recherche sur le Temps Biologique et la Chimiothérapie (ARTBC, Villejuif, 2002-)

  • Coordinateur Général du Programme de soins oncologiques du CHC-Liège (2003), Président de la CPO (Commission Pluridisciplinaire d'Oncologie du CHC, 2003- )

  • Membre du Groupe de travail Oncologie – INAMI (2007- )

  • Membre de la Commission d'Agrément en Oncologie – Ministère de la santé (2007-  )

Publications

  • de Azambuja E, Paesmans M, Beauduin M, Vindevoghel A, Cornez N, Finet C, Ries F, Closon-Dejardin MT, Kerger J, Gobert P, Focan C, Tagnon A, Dolci S, Nogaret JM, di Leo A, Piccart-Gebhart MJ. Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study. J Clin Oncol. 2008 Dec 22.

  • Demolin G, Focan C, Plomteux O, Kreutz F, Moeneclaey N, Focan-Henrard D. Chemotherapy for human gastric cancer: a review. Rev Med Liege. 2008 Sep; 63(9): 532-41.

  • Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008 Dec 1; 26(34): 5569-75. Epub 2008 Nov 3.

  • Coudert B, Focan C, Genet D, Giacchetti S, Cvickovic F, Zambelli A, Fillet G, Chollet P, Amoroso D, Van Der Auwera J, Lentz MA, Marreaud S, Baron B, Gorlia T, Biville F, Lévi F. A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971. Chronobiol Int. 2008 Sep; 25(5): 680-96.

  • Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B; C-100-12 RCC Study Group. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.Lancet. 2008 Jul 12; 372(9633): 145-54.

  • Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D, Tampellini M, Bottomley A, Garufi C, Focan C, Giacchetti S, Lévi F; Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2008 Apr 20; 26(12): 2020-6.

  • Lévi F, Focan C, Karaboué A, de la Valette V, Focan-Henrard D, Baron B, Kreutz F, Giacchetti S. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 2007 Aug 31; 59(9-10): 1015-35. Epub 2007 Jul 4.

  • Matus G, Dicato M, Focan C. Cancer associated retinopathy (CAR). Two clinical cases and review of the literature. Rev Med Liege. 2007 Mar; 62(3): 166-9.

  • Focan C, Kreutz F, Longrée L, Graas MP, Moeneclaey N, Demolin G, Focan-Henrard D. Interest of chronotherapy in multidisciplinary management of oesophageal and gastric cancers. Pathol Biol (Paris). 2007 Apr-May; 55(3-4): 181-5.

  • Focan C, Lévi F, Innominato P. Circadian behaviour of host versus tumour outcome. A review. Pathol Biol (Paris). 2007 Apr-May; 55(3-4): 178-80.

  • Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Lévi F; European Organisation for Research and Treatment of Cancer Chronotherapy Group. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 2006 Aug 1; 24(22): 3562-9.

  • Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, Fountzilas G, Paul J, Rosso R, Venturini M. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol. 2005 Aug 1; 23(22): 5117-25.

  • Focan C, Bury J, Matus G, Graas MP, Kreutz F, Longree L, Moeneclaey N, David A, Focan-Henrard D. Adjuvant chemotherapy for Dukes B2 and C colon cancer combining 5-fluorouracil and folinic acid with or without carboplatin. Feasibility and comparison between standard and chronomodulated deliveries. Pathol Biol (Paris). 2005 Jun; 53(5): 281-4.

  • Focan C, Kreutz F, Graas MP, Longrée L, Moeneclaey N, David A, Focan-Henrard D. Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer. Pathol Biol (Paris). 2005 Jun; 53(5): 277-80.

  • Focan C, Kreutz F, Longrée L, Graas MP, Focan-Henrard D, Moeneclaey N, David A, Biquet JF, Materne R, Weerts J, Delforge M. Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study. Pathol Biol (Paris). 2005 Jun; 53(5): 273-6.

  • Focan C, Graas MP, Beauduin M, Canon JL, Salmon JP, Jerusalem G, Focan-Henrard D, Lobelle JP, Schallier D. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial. Anticancer Res. 2005 Mar-Apr;25(2B): 1211-7.

  • Li XM, Tanaka K, Sun J, Filipski E, Kayitalire L, Focan C, Lévi F. Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin. Br J Cancer. 2005 May 9; 92(9): 1684-9.

  • Focan C., Kreutz F., Moeneclaye N., Focan-Henrard D. "Randomised study to evaluate the chronotolerance of a combination infusional chemotherapy with 5-fluorouracil, folinic acid and carboplatin in non small cell lung cancer (NSCLC) patients", Pathol. Biol (Paris), 2003 Jun, 51(4):204-5

  • Ferreira Filho AF., Di Leo A., Paesmans M., Beauduin M., Vindevoghel A., Michel J., Focan C. "The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses accross institutions", Ann Oncol, 2002 Mar, 13(3): 416-21

  • Cure H., Chevalier V., Adenis A., Tubiana-Mathieu N., Niezgodzki G., Kwiatkowski F., Pezet D., Perpoint B., Coudert B., Focan C., Levi F., Chipponi J., Chollet P. "Phase II trial of chronomodulated infusion of high-dose fluorouracil and 1-folinic acid in previously untreated patients with metastatic colorectal cancer", J Clin Oncol, 2002 Mar, 20(5): 1175-81

  • Coudert B., Focan C., Donato di Paola E., Levi F., EORTC Chronotherapy Group. "It's time for chronotherapy!", Eur J Cancer, 2002 Mar, 38 Suppl 4:S50-3

  • Bonneterre J., Chevalier B., Focan C., Mauriae L., Piccart M. "Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC)", Ann Oncol, 2001 Dec, 12(12): 1683-91

Communications scientifiques (communications orales, posters)

  • Chemotherapy for the muldisciplinary management of urothelial and prostate cancer. GLEM urologie, 09/05/2006.

  • Pharmaco-économie des thérapies ciblées. GLEM onco-hematologie, 19/04/2007. 

  • Quadri-chronochemotherapy with 5-FU, folinic acid, carboplatin and irinotecan for metastatic colorectal cancer. The BE1-603 Phase I-II study. ICACC 2007.

  • Chronotherapy with 5-fu,folinic acid and carboplatin for advanced biliary tract cancer. A pilot study. ICACC 2007. 

  • Chrono-Tegafox. A randomized phase II trial in first line metastatic colorectal elderly cancer patients.

  • Standard vs chronomodulated treatment. ICACC 2007.

  • Gender-effect in nsclc treated by chronotherapy with 5-fu, folinic acid and carboplatine. From a randomized phase I to a phase II study. ICACC 2007.

  • Chronobiological concepts for the management of human lung cancer. International forum of chronomedicine, Zhuhai, China, 2007. 

  • Influence des rythmes biologiques et du stress sur l'évolution du cancer. Symposium « Le cancer traité... Et après ? » au CHC, Liège, le 08/11/2008.

  • Prise en charge médicale du cancer colique métastatique Drs Gauthier Demolin, Olivier Plomteux et Christian Focan Journée médicale du CHC, Liège, le 07/10/2006.

  • Prise en charge pluridisciplinaire des tumeurs de la tête et du cou: Guidelines 2006. Symposium organisé sous les auspices de la Commission Pluridisciplinaire d'Oncologie du CHC Liège le 20/01/2006.

  • Plan Cancer Belge : Projet pilote d'onco-gériatrie. CHC-Liège.

  • L'onco-gériatrie au CHC

Cours

  • Chronobiologie et chronopharmacologie. Cours de pharmacocinétique ULg, 04/12/2007.